Research keywords (2)：
脳神経外科学
, Neurological Surgery
Research theme for competitive and other funds (8)：
2019 - 2022 Correlation between molecular imaging and pathological and genetic analysis in brain tumors
2014 - 2017 Molecular therapy for malignant brain tumors using microRNAs of drug-resistant genes
2010 - 2012 Gene and molecular therapy for malignant brain tumors using drug-resistant genes
2005 - 2007 GENE AND MOLECULAR THERAPY FOR MALIGNANT BRAIN TUMORS USING NEURAL STEM CELLS DERIVED FROM EMBRIONIC STEM CELLS
2005 - 2006 悪性脳腫瘍に対する遺伝子解析に基づいたテーラーメイド治療
1994 - 抗ガン剤耐性機構
The mechanism for multiple resistance of anti-cancer drugs
The mechanism for multiple resistance of anti-cancer drugs
Show all
Papers (76)：
Taketo Ezaki, Toshihide Tanaka, Ryota Tamura, Kentaro Ohara, Yohei Yamamoto, Jun Takei, Yukina Morimoto, Ryotaro Imai, Yuki Kuranai, Yasuharu Akasaki, et al. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. Brain Tumor Pathology. 2024. 41. 2. 61-72
Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Kyoichi Tohmoto, Yuki Kuranari, Ryotaro Imai, Yohei Yamamoto, Yuzuru Hasegawa, et al. 10001-ACT-1 A MULTICENTER EXPLORATORY PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB FOR NEWLY DIAGNOSED MALIGNANT GLIOMA - THE SECOND REPORT. Neuro-Oncology Advances. 2023. 5. Supplement_5. v1-v1
Kenta Suzuki, Daisuke Ogawa, Takahiro Kanda, Takeshi Fujimori, Yuki Shibayama, Asadur Rahman, Juanjuan Ye, Hiroyuki Ohsaki, Kazuya Akimitsu, Ken Izumori, et al. Antiproliferative effects of D-allose associated with reduced cell division frequency in glioblastoma. Scientific Reports. 2023. 13. 1
Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Yohei Yamamoto, Ryotaro Imai, Yuki Kuranai, Kyoichi Tohmoto, Yuzuru Hasegawa, et al. An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma. 2023
Tomoya Suzuki, Jun Takei, Nei Fukasawa, Kenta Suzuki, Daisuke Ogawa, Yohei Yamamoto, Yasuharu Akasaki, Yuichi Murayama, Masayuki Shimoda, Keisuke Miyake, et al. FMISO-PET and immunohistochemistry verified tumor oxygenation, stemness, and immunosupportive microenvironment after preoperative neoadjuvant bevacizumab for newly diagnosed glioblastoma. World neurosurgery. 2023. 175. e1364-e1374
Ezaki T, Tanaka T, Tamura R, Yamamoto Y, Takei J, Morimoto Y, Imai R, Kuranari Y, Akasaki Y, Murayama Y, et al. ANGI-1 Regulation of alternative angiogenic factors in bevacizumab therapy for glioblastoma. Neuro-Oncology Advances. 2023. 5. 5. v1-v2
Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Tohmoto K, K, Kuranari Y, Imai R, Yamamoto Y, et al. A prospective multicenter phase I/IIa study of prospective neoadjuvant bevacizumab for newly diagnosed glioblastoma. Neuro-Oncology Advances. 2022. 4. 3. iii7
1997 - 2000 1994-1997 postgraduate student. Kagawa medical University. a postgraduate course 1997-2000 Research fellow National Cancer Institute National Institute of Health, research fellow
Show all
Awards (2)：
1999 - 1999 AACR-Bristol-Myers Squibb Oncology Young Investigator Awards
1999 - 1999 AACR-Bristol-Myers Squibb Oncology Young Investigator Awards
Association Membership(s) (14)：
日本脳神経外科コングレス
, 日本脳腫瘍学会
, 日本小児神経外科学会
, 日本脳腫瘍病理学会
, 日本癌学会
, 日本癌治療学会
, 日本脳神経外科学会
, The JAPANESE CONGRESS OF NEUROLOGICAL SURGEONS
, The Japan Society for Neuro-Oncology
, The Japanese Society for Pediatric Neurosurgery
, Japan Society for Brain Tumor Pathology
, The Japanese Cancer Association
, The Japan Society of Clinical Oncology
, 日本脳神経外科学会
